[Development of human monoclonal antibodies] [Article in German]

Toni Lindl

pdf

Published: Feb 1, 1995

Keywords:

human monoclonal antibodies, in vitro immunization, somatic cell fusion, Epstein Barr virus transformation, human immunoglobulin gene libraries, phage display techniques

Toni Lindl
[show affiliations]

Abstract

This article describes the current state of the development of human monoclonal antibodies. The last three years brought a wealth of new techniques and it seems that the long-awaited breakthrough of these "magic" therapeutic agents is close. This paper discusses both the classical cell-biological methods (e.g. fusion with other lymphoma cells and/or Epstein Barr virus transformation of human B-cells) and the "new" gene-technology approaches. The therapeutic possibilities of human monoclonal antibodies against infectious agents and cancer related antigens and their impact are reviewed and the development strategies - both "classical" and "new" - are discussed. The in vitro immunisation technique is critically reviewed.

How to Cite

Lindl, T. (1995) “[Development of human monoclonal antibodies] [Article in German]”, ALTEX - Alternatives to animal experimentation, 12(1), pp. 13–23. Available at: https://altex.org/index.php/altex/article/view/1683 (Accessed: 16 May 2025).

Issue

Vol. 12 No. 1 (1995)

Section

Articles

Articles are distributed under the terms of the Creative Commons Attribution 4.0 International license (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium, provided the original work is appropriately cited (CC-BY). Copyright on any article in ALTEX is retained by the author(s).

Most read articles by the same author(s)

Toni Lindl, Ulrike Gross, Irmela Ruhdel, Sonja von Aulock, Manfred Völkel, Erratum to Guidance on Determining Indispensability and Balancing Potential Benefits of Animal Experiments with Costs to the Animals with Specific Consideration of EU Directive 2010/63/EU , ALTEX - Alternatives to animal experimentation: Vol. 29 No. 4 (2012)
Toni Lindl, Ulrike Gross, Irmela Ruhdel, Sonja von Aulock, Manfred Völkel, Guidance on determining indispensability and balancing potential benefits of animal experiments with costs to the animals with specific consideration of EU Directive 2010/63/EU , ALTEX - Alternatives to animal experimentation: Vol. 29 No. 2 (2012)
Toni Lindl, Manfred Voelkel, No clinical relevance of approved animal experiments after seventeen years , ALTEX - Alternatives to animal experimentation: Vol. 28 No. 3 (2011)
Lavinia Stingl, Manfred Völkel, Toni Lindl, 20 years of hypertension research using genetically modified animals: no clinically promising approaches in sight , ALTEX - Alternatives to animal experimentation: Vol. 26 No. 1 (2009)
Toni Lindl, Manfred Völkel, Roman Kolar, [Animal experiments in biomedical research. An evaluation of the clinical relevance of approved animal experimental projects: No evident implementation in human medicine within 10 years] [Article in German] , ALTEX - Alternatives to animal experimentation: Vol. 22 No. 3 (2005)
Toni Lindl, Ingrid Weichenmeier, Dirk Labahn, Franz P. Gruber, Manfred Völkel, [Evaluation of authorised experiments on laboratory animals with regard to the following frame of reference: The aim of the research to be carried out, its scientific usefulness and its medical relevance] [Article in German] , ALTEX - Alternatives to animal experimentation: Vol. 18 No. 3 (2001)
Toni Lindl, [Mass production of monoclonal antibodies: Technical, scientific and ethical considerations] [Article in German] , ALTEX - Alternatives to animal experimentation: Vol. 5 No. 1 (1988)

Article Sidebar

Main Article Content

Abstract

Article Details

Most read articles by the same author(s)